HCW Biologics Inc.
HCWB
$2.06
$0.073.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -96.34% | -98.93% | -99.55% | -70.18% | -50.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.34% | -98.93% | -99.55% | -70.18% | -50.02% |
| Cost of Revenue | -96.34% | -98.81% | -99.20% | -70.52% | -49.71% |
| Gross Profit | -96.37% | -99.28% | -99.84% | -68.73% | -51.20% |
| SG&A Expenses | -26.46% | -81.14% | -58.15% | -60.53% | -27.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.54% | -75.99% | -53.94% | -59.85% | -30.69% |
| Operating Income | 10.65% | 74.96% | 47.08% | 58.58% | 27.44% |
| Income Before Tax | -16.71% | 87.38% | 70.58% | 68.42% | 20.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.71% | 87.38% | 70.58% | 68.42% | 20.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.71% | 87.38% | 70.58% | 68.42% | 20.98% |
| EBIT | 10.65% | 74.96% | 47.08% | 58.58% | 27.44% |
| EBITDA | 12.31% | 76.86% | 51.08% | 64.00% | 25.92% |
| EPS Basic | 51.17% | 58.00% | 75.49% | 73.12% | 24.94% |
| Normalized Basic EPS | 61.53% | 86.03% | 53.18% | 62.77% | 24.95% |
| EPS Diluted | 51.17% | 58.00% | 75.49% | 73.12% | 24.94% |
| Normalized Diluted EPS | 61.53% | 86.03% | 53.18% | 62.77% | 24.95% |
| Average Basic Shares Outstanding | 139.01% | 88.25% | 20.02% | 17.51% | 5.28% |
| Average Diluted Shares Outstanding | 139.01% | 88.25% | 20.02% | 17.51% | 5.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |